Eli Lilly Sues Teva Again Over Gemzar ANDA
In a complaint filed Friday in the U.S. District Court for the Southern District of Indiana, Lilly claims Teva's application with the U.S. Food and Drug Administration to make generic Gemzar infringes U.S. Patent Numbers 4,808,614 and 5,464,826.
The '614 patent relates to the pharmaceutical makeup of the drug and is scheduled to expire in May 2010. The '826 patent,...
To view the full article, register now.